Safety profile of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis: long-term interim results from the ENDORSE extension study

被引：0
|
作者：
Phillips, J. T. [1 ]
Fox, R. J. [2 ]
Selmaj, K. [3 ]
Yang, M. [4 ]
Zhang, R. [4 ]
Novas, M. [4 ]
Sweetser, M. T. [4 ]
Viglietta, V. [4 ]
Gold, R. [5 ]
机构：
[1] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[2] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[3] Med Univ Lodz, Lodz, Poland
[4] Biogen Idec Inc, Weston, MA USA
[5] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：457 / 457
页数：1
相关论文
共 50 条
  • [1] Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: interim results from ENDORSE
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Raghupathi, K.
    O'Gorman, J.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 517 - 518
  • [2] Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): Interim Results from ENDORSE Extension Study
    Phillips, J. Theodore
    Fox, Robert
    Selmaj, Krzysztof
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Sweetser, Marianne
    Viglietta, Vissia
    Dawson, Katherine
    Gold, Ralf
    NEUROLOGY, 2013, 80
  • [3] Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Pozzilli, C.
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 678 - 678
  • [4] Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Pozzilli, C.
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S439 - S439
  • [5] Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study
    Kita, M.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Sarda, S. P.
    Kong, J.
    Zhang, R.
    Viglietta, V.
    Sheikh, S. I.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 530 - 530
  • [6] Efficacy and Safety of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis in the Phase 3 CONFIRM Study
    Hutchinson, M.
    Fox, R. J.
    Phillips, J. T.
    Miller, D. H.
    Havrdova, E.
    Kita, M.
    Yang, M.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 683 - 683
  • [7] Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis
    Kappos, Ludwig
    Giovannoni, Gavin
    Gold, Ralf
    Fox, Robert
    Phillips, J. Theodore
    Hotermans, Christophe
    Zhang, Annie
    Viglietta, Vissia
    Miller, David
    NEUROLOGY, 2013, 80
  • [8] Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
    Nielsen, A. Scott
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2015, 5
  • [9] THE COST EFFECTIVENESS OF BG-12 (DIMETHYL FUMARATE) FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
    Su, W.
    Walker, A.
    Sarda, S.
    Kansal, A. R.
    Vicente, C.
    Deniz, B.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
  • [10] Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis
    Ruggieri, Serena
    Tortorella, Carla
    Gasperini, Claudio
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 229 - 239
12345